Bravecto Dosage Calculator for Dogs

What Is a Bravecto Dosage Calculator for Dogs?

A Bravecto dosage calculator helps dog owners and veterinary nurses identify the correct Bravecto product weight band for a dog and understand the dosing interval, ensuring accurate flea and tick prevention without under- or over-dosing. Bravecto (active ingredient: fluralaner) is a veterinary-prescription isoxazoline antiparasitic licensed for the treatment and prevention of flea infestations (Ctenocephalides felis and C. canis) and tick infestations (including Ixodes ricinus, Dermacentor reticulatus, and Rhipicephalus sanguineus) in dogs. It is available in the United Kingdom and Europe as both a chewable tablet (administered orally with food) and a spot-on pipette (applied to the skin at the back of the neck), with the spot-on formulation providing an additional licensed indication against some biting louse species.

Bravecto is categorised by weight band rather than by precise milligram per kilogram dosing, as is common with many veterinary antiparasitic products. Each weight band is formulated to deliver approximately 25 to 56 mg of fluralaner per kilogram of body weight, a dose range that covers the minimum effective concentration across the full weight band. The weight bands for the chewable tablet in the UK are: 2–4.5 kg, 4.5–10 kg, 10–20 kg, 20–40 kg, and 40–56 kg. The spot-on formulation uses the same five weight bands. Dogs whose weight falls at the upper end of a weight band receive a lower mg/kg dose than dogs at the lower end, but clinical trials have confirmed efficacy across the full range. Dogs must be within the licensed weight range; dogs above 56 kg require veterinary guidance on appropriate combination dosing.

The standard dosing interval for Bravecto chewable tablets is 12 weeks (3 months) for flea and tick prevention, which is one of the longest treatment intervals of any licensed small animal ectoparasiticide and a key practical advantage for owners compared to monthly topical treatments. The Bravecto spot-on has different licensed intervals depending on the parasite: 12 weeks for flea and most tick species, but only 8 weeks for Ixodes ricinus (the castor bean tick, the primary Lyme disease vector in the UK). This distinction is important for owners in tick-endemic areas of the UK, particularly in Scotland, the New Forest, the South Downs, the Lake District, and coastal areas of Wales, where I. ricinus is prevalent and Lyme disease risk is meaningful. Owners in these areas using the spot-on formulation should re-apply at 8 weeks rather than 12. The Dog Dosage Calculator covers general weight-based medication dosing, while this tool is specific to Bravecto weight band selection and treatment scheduling.

Bravecto is a prescription-only medicine (POM-V) in the United Kingdom, meaning it is available from a veterinary surgeon or on a veterinary prescription from a licensed online pharmacy. The prescription-only status exists because fluralaner belongs to the isoxazoline class, which has a small but documented risk of neurological adverse events in individual dogs, particularly in those with a history of neurological conditions. The European Medicines Agency and Veterinary Medicines Directorate have reviewed the safety profile of fluralaner and the isoxazoline class and determined that it remains approvable with appropriate prescribing controls. Dogs with a known history of epilepsy or neurological disease should have Bravecto use discussed explicitly with their prescribing vet before initiation. For owners using Bravecto as part of a parasite control plan that also includes regular worming, the Dog Dosage Calculator supports weight-based dosing calculations for separately prescribed worming products.

How to Use the Bravecto Dosage Calculator for Dogs

1. Enter the dog's current body weight: Use the most recent accurate weight measurement. If the dog's weight has changed since their last Bravecto prescription, the weight band may have changed and the appropriate product needs to be confirmed with the prescribing vet. Weigh the dog before each treatment cycle, particularly for puppies and young dogs whose weight can change substantially over a 12-week period.
2. Select the product formulation: Choose between chewable tablet and spot-on. Both contain fluralaner but are administered differently. The chewable tablet should be given with food or immediately after a meal to maximise absorption. The spot-on should be applied to intact, unbroken skin at the base of the skull; the dog should not be bathed or allowed to swim for 48 hours after application.
3. Select the geographic tick risk: For spot-on users in tick-endemic UK areas where I. ricinus is present, select high tick risk to receive the 8-week re-treatment reminder. For dogs in lower-risk areas or those using the chewable tablet, the standard 12-week interval applies.
4. Read the weight band and next treatment date: The calculator returns the correct Bravecto weight band, the product SKU reference, and the next scheduled treatment date based on today's date and the applicable dosing interval.

Bravecto Weight Bands and Fluralaner Content

The following table shows the five licensed weight bands for Bravecto in the UK, the corresponding fluralaner content, and the approximate mg/kg dose range delivered across each band:

• 2 to 4.5 kg: Bravecto 112.5 mg chewable tablet. Dose range: 25 mg/kg (at 4.5 kg) to 56.25 mg/kg (at 2 kg). Minimum eligible age: 8 weeks of age and minimum body weight 2 kg.
• 4.5 to 10 kg: Bravecto 250 mg chewable tablet. Dose range: 25 mg/kg (at 10 kg) to 55.6 mg/kg (at 4.5 kg).
• 10 to 20 kg: Bravecto 500 mg chewable tablet. Dose range: 25 mg/kg (at 20 kg) to 50 mg/kg (at 10 kg).
• 20 to 40 kg: Bravecto 1,000 mg chewable tablet. Dose range: 25 mg/kg (at 40 kg) to 50 mg/kg (at 20 kg).
• 40 to 56 kg: Bravecto 1,400 mg chewable tablet. Dose range: 25 mg/kg (at 56 kg) to 35 mg/kg (at 40 kg).

The minimum effective dose of fluralaner for flea and tick control is 25 mg/kg body weight. The product is formulated so that the smallest dog in each weight band receives the highest mg/kg dose (approximately 50 to 56 mg/kg) and the largest dog receives the minimum effective dose (25 mg/kg). This formulation strategy ensures that all dogs within the band receive at least the minimum effective dose, with the additional safety margin at the low end of each band providing further buffer against any underestimation of body weight at dosing.

Real-World Applications

A Golden Retriever weighing 34 kg is prescribed Bravecto by her vet for flea and tick prevention. She falls in the 20 to 40 kg weight band and receives the 1,000 mg chewable tablet at her check-up in March. Her owner sets a reminder for 12 weeks later in early June for the next dose. Her weight is stable at annual check-ups so the band does not change. Her owner gives the tablet with her morning meal and monitors her for 24 hours after each dose as recommended.

A Cocker Spaniel weighing 12 kg who lives in the New Forest uses the Bravecto spot-on formulation. He falls in the 10 to 20 kg spot-on band. His owner, who is aware of the higher I. ricinus risk in their area, follows the 8-week re-treatment schedule for the spot-on rather than 12 weeks. She applies the spot-on to the skin at the base of his neck and keeps him out of the river for 48 hours after each application.

A seven-week-old Border Collie puppy weighing 1.8 kg is brought to a vet clinic. The vet advises that Bravecto is not yet appropriate: the minimum eligible weight is 2 kg and minimum age is 8 weeks. The vet prescribes a licensed flea product for puppies below 2 kg and schedules review of the Bravecto prescription for when the puppy exceeds 2 kg and reaches 8 weeks of age simultaneously.

Bravecto in the Context of a Complete Parasite Control Plan

Bravecto addresses only ectoparasites: fleas, ticks, and (with the spot-on formulation) some lice species. A complete parasite control programme for a UK dog also requires regular treatment for intestinal worms (roundworm, tapeworm, and hookworm), lungworm, and heartworm in dogs travelling to or living in endemic regions. Bravecto does not treat any of these endoparasite groups, and owners should not assume that a Bravecto prescription covers the full range of parasites their dog may be exposed to.

In the United Kingdom, the most clinically significant endoparasite for which additional prophylaxis is strongly recommended is Angiostrongylus vasorum (French lungworm), which is transmitted by the ingestion of infected slugs and snails and has a significant geographic prevalence in southern England, Wales, and parts of the Midlands. The disease can be fatal if untreated and does not respond to standard over-the-counter worming products. Licensed prescription products containing milbemycin oxime (Milbemax) or moxidectin (Advocate, Bravecto Plus in cats) are required for lungworm prevention, given monthly. For dogs prescribed Bravecto for ectoparasite control, the prescribing vet should confirm that a separate lungworm prevention protocol is also in place unless the dog is in a demonstrably low-risk area. The two treatments are typically given on a staggered calendar to reduce the number of treatments on any single day.

Intestinal worm treatment frequency in UK dogs is typically every three months with a licensed wormer for dogs with access to the outdoors, scavenging behaviour, or raw meat feeding. Dogs who hunt, eat raw meat, or have regular contact with children may require more frequent worming, as some roundworm species (Toxocara canis) are zoonotic and can cause ocular and visceral toxocariasis in humans, particularly in young children. The parasite control plan prescribed by a vet takes all of these factors into account alongside Bravecto, resulting in a combined monthly and quarterly treatment calendar that protects the dog against the full range of parasites likely to be encountered in its specific lifestyle and geographic environment.

Common Mistakes

Not weighing the dog before each treatment cycle: Dogs, particularly puppies, adolescents, and dogs recovering from illness, can change weight band over a 12-week period. Using the previously prescribed weight band without confirming current weight may mean the dog receives a dose formulated for a lower or higher weight range than their actual weight. Puppies growing rapidly during the first 12 to 18 months of life should be weighed before each Bravecto prescription is issued.

Using the chewable tablet interval for the spot-on when in a high-tick-risk area: The Bravecto spot-on's licensed duration of activity against Ixodes ricinus is 8 weeks, not 12 weeks. Owners who treat at the chewable-tablet interval of 12 weeks are leaving their dogs unprotected for up to 4 weeks against I. ricinus during the tick transmission window. This distinction is clinically significant in Lyme disease-endemic areas and is one of the most common prescribing errors with this product class.

Bathing or allowing the dog to swim immediately after spot-on application: The spot-on formulation requires time to distribute across the skin surface via the lipid layer of the coat. Bathing or swimming within 48 hours of application can reduce efficacy by washing away the product before distribution is complete. For dogs who swim frequently, the chewable tablet formulation may offer more reliable coverage because its efficacy does not depend on surface-level absorption.

Treating dogs under 8 weeks of age or below 2 kg: Bravecto is not licensed for dogs under 8 weeks of age or below 2 kg body weight. The safety profile of fluralaner in very young or very small dogs has not been established in clinical trials for these weight and age categories. A licensed flea product appropriate for the animal's actual size and age should be used until the dog meets the minimum eligibility criteria.